According to Deep Tide TechFlow news, on July 7, the publicly traded company Aditxt, Inc. (NASDAQ: ADTX) announced the launch of the bitXbio™ program today, which is an innovative financial strategy combining Bitcoin reserves with equity financing. The program aims to support the company's biotechnology commercialization efforts, particularly for potential monetization events targeting 2026, including the planned IPO of its subsidiary Pearsanta.
Aditxt currently operates two projects focused on autoimmune diseases and early disease detection, which will establish a Bitcoin reserve based on the availability of funds and strategically utilize the existing approximately $125 million equity financing capacity. The company's CEO Amro Albanna stated that this move will help Aditxt strengthen its balance sheet and enhance corporate value, creating more value for shareholders.
